Elizabeth McKee Anderson
About Elizabeth McKee Anderson
Elizabeth McKee Anderson (age 67) is an independent Class I director of Revolution Medicines, serving since March 2015. She brings extensive commercial leadership experience from Janssen/Johnson & Johnson and Wyeth Lederle Vaccines, and currently serves on the boards of GSK Plc, BioMarin Pharmaceutical, and Insmed. She holds a B.Eng. from Rutgers University and an MBA in Finance from Loyola University Maryland .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Janssen Pharmaceuticals (J&J) | Worldwide VP, Commercial Leader, Infectious Diseases & Vaccines; Worldwide VP, Global Strategic Marketing & Market Access, Vaccines | 2010–2014 (lead roles); 2003–2014 (various) | Led vaccine strategy and market access; significant commercial leadership |
| Wyeth Lederle Vaccines | Vice President & General Manager | Prior to 2003 | General management across vaccines business |
External Roles
| Organization | Role | Start Date |
|---|---|---|
| GSK Plc (NYSE: GSK) | Director | Sept 2022 |
| BioMarin Pharmaceutical (Nasdaq: BMRN) | Director | July 2019 |
| Insmed Inc. (Nasdaq: INSM) | Director | Nov 2018 |
Board Governance
- Independence: Board determined all directors except the CEO are independent under Nasdaq rules; Anderson is independent .
- Committee assignments: Chair, Compensation Committee; Member, Commercialization Committee .
- Lead Independent Director: Alexis Borisy serves as Lead Independent Director .
- Executive sessions: Independent directors meet in regularly scheduled executive sessions .
- Attendance and engagement: In 2024, the Board met 8x; Compensation 7x; Audit 4x; Nominating 3x; R&D 4x; Commercialization 1x. Each director attended at least 75% of meetings; all nine then-serving directors attended the 2024 annual meeting .
Fixed Compensation
- Structure (2024): Annual director cash retainer $45,000; committee chair/member fees: Audit Chair $20,000 (members $10,000); Compensation Chair $15,000 (members $7,500); Nominating Chair $10,000 (members $5,000); R&D Chair $15,000 (members $7,500); Commercialization Chair $15,000; Commercialization members $7,500 .
- Update (effective as of 2025 Annual Meeting): Annual director cash retainer increased to $50,000; Compensation Committee Chair to $18,000; Compensation Committee member to $9,000 .
- Meeting fees: Not disclosed (no per-meeting fees listed) .
Director compensation – recent years (USD):
| Year | Cash Fees | Stock Awards (RSUs FV) | Option Awards (FV) | Total |
|---|---|---|---|---|
| 2024 | $62,099 | $159,470 | $371,555 | $593,124 |
| 2023 | $57,813 | $129,168 | $296,799 | $483,780 |
Performance Compensation
- Equity program (2024): Annual Grant targeted 16,700 options and 4,800 RSUs, capped at $550,000 aggregate grant-date fair value; due to the cap, directors received 15,955 options and 4,248 RSUs; Annual Option vests by first anniversary or immediately prior to next annual meeting; Annual RSUs vest by first anniversary of first quarterly vest date or immediately prior to next annual meeting; quarterly vest dates are Mar 15, Jun 15, Sep 15, Dec 15 .
- Equity program (Initial Grant): 33,400 options + 9,600 RSUs; options vest monthly over 3 years; RSUs vest quarterly over 3 years .
- Update (effective as of 2025 Annual Meeting): Annual Grant changed to value-based award with $417,000 grant-date fair value (70% options, 30% RSUs); Initial Grant $834,000 (70% options, 30% RSUs) .
2024 director equity position at year-end (units outstanding):
| Instrument | Quantity |
|---|---|
| Options outstanding | 102,823 |
| RSUs outstanding | 4,248 |
Other Directorships & Interlocks
- Industry overlap: Anderson’s roles at GSK, BioMarin, and Insmed create broad biopharma network exposure; no RVMD-related party transactions disclosed involving Anderson .
- Related-party controls: RVMD maintains a related person transaction policy with Audit Committee approval required; recent collaboration disclosed with Tango Therapeutics involves other directors (Weber, Borisy), not Anderson .
Expertise & Qualifications
- Deep commercial leadership in vaccines and market access (Janssen; Wyeth), aligning with RVMD’s Commercialization Committee work .
- Education: B.Eng., Rutgers; MBA (Finance), Loyola University Maryland .
Equity Ownership
Beneficial ownership and alignment:
| As of March 31, 2025 | Shares Owned (direct + trust) | Options Exercisable ≤60 days | Total Beneficial | % Outstanding |
|---|---|---|---|---|
| Elizabeth McKee Anderson | 42,815 (15,825 direct; 26,990 trust) | 86,868 | 129,683 | <1% |
- Anti-hedging/pledging: RVMD policy prohibits hedging and pledging by directors and officers .
- Vested vs unvested: Beneficial table includes only options exercisable within 60 days; unexercisable/longer-dated holdings are not counted in beneficial ownership .
Governance Assessment
- Committee leadership: As Compensation Committee Chair, Anderson oversees executive and director pay with independent consultant support (Compensia), which affirmed independence; no interlocks or insider participation reported—strong governance practice .
- Shareholder support: Say-on-Pay approval ~99% in 2024 indicates broad investor confidence in compensation oversight .
- Attendance: Board and committee attendance thresholds met; multiple meetings held, signaling active engagement .
- Independence: Board confirms Anderson’s independence; regular executive sessions bolster oversight .
- Compensation structure: Director pay mix emphasizes equity (options/RSUs) with a capped grant fair value and option-heavy allocation (70%), aligning directors with long-term shareholder value; cash retainer increases in 2025 reflect expanded responsibilities and market alignment .
- Conflicts: No related-party transactions involving Anderson disclosed; insider trading policy prohibits hedging/pledging—no pledging indicated in ownership disclosures .
- RED FLAGS: None disclosed specific to Anderson. Monitor potential time-commitment risk from multiple public boards, though RVMD attendance and engagement metrics were solid in 2024 .
Overall investor-confidence signals: high Say-on-Pay approval, independent compensation governance under Anderson, and strong attendance; no Anderson-related party transactions disclosed .